Brought to you by 
Pernix sells some Cypress assets to Breckenridge for $30mm
30 Jan 2023
Executive Summary
Generics maker Breckenridge Pharmaceutical Inc. has paid $20mm up front in cash to acquire assets from Cypress Pharmaceutical, an absorbed division of Pernix Therapeutics Holdings Inc. (brand, generic, and OTC products). Breckenridge is also entitled to a deferred payment of $10mm, consisting of two $5mm unsecured promissory notes due on the first and second anniversaries of the deal.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pernix sells some Cypress assets to Breckenridge for $30mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice